HOME >> BIOLOGY >> NEWS
'Second messenger' NAADP shows fast, dose-related impact on satiety cycle

San Diego (April 3, 2005) One traditional approach to pharmaceutical design uses so-called "first messengers" hormones, other natural facilitators or synthetic products to initiate various cellular cascades for the desired physiological effect. To date, despite concerted efforts at all levels of research, this approach has failed to develop a truly successful obesity drug to address this major global health problem.

Enter a recently discovered and already controversial natural molecule called nicotinic acid adenine dinucleotide phosphate (NAADP), which is active in cells from plants to humans. NAADP is thought to be a so-called "second messenger," because it works from inside cells, rather than externally. However its mode operation remains unknown and controversial in several aspects.

Results of a new study "establishes NAADP as a new second messenger, and the study of this novel molecule has potential to extend its clinical significance, possibly as a candidate for treating obesity," according to the lead author, Michiko Yamasaki at the Department of Pharmacology, University of Oxford, United Kingdom.

Yamasaki is presenting the research at the 35th Congress of the International Union of Physiological Sciences in San Diego, March 31 - April 5, 2005.

*Paper presentation and "controversy" appearance: "Rapid, selective and dose-dependent elevation of the second messenger NAADP," 12:30 p.m.-3 p.m. Tuesday April 5, Physiology 932.3/board #A438. On view 7:30 a.m. - 4 p.m.

In addition, Ms. Yamasaki was chosen to participate in a special "controversy" session #654 of the Calcium Signaling Track on April 4 in room 29C of the Convention Center beginning at 10:30; her presentation is scheduled for 11:45 a.m.

The team working on the study was comprised of Michiko Yamasaki, Grant Churchill and Antony Galione at the Department of Pharmacology, University of Oxford; Sandip Patel at University College London; and Jose M. Cancel
'"/>


3-Apr-2005


Page: 1 2 3

Related biology news :

1. Clones on task serve greater good, evolutionary study shows
2. Research shows skeleton to be endocrine organ
3. An early ape shows its hand
4. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
5. Huntingtons disease study shows animal models on target
6. Research shows NPD1 protects a key component of vision
7. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
8. Chitin from lobster shell shows great healing and bio-stimulant properties
9. Study shows cane sugar, corn sweeteners have similar effects on appetite
10. New research shows vaginal bacteria vary among healthy women, need customized treatment
11. Global warming is evaporating Arctic ponds, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
Cached News: